CRIS

Business Context and Reporting Period

Company: Curis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Business Overview: Curis is a regenerative medicine company formed on July 31, 2000, through the merger of Creative BioMolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc. The company focuses on harnessing functional genomics and developmental biology to develop therapies for tissue repair, organ regeneration, and cancer treatment. Key product candidates include Chondrogel (vesicoureteral reflux), Vascugel (restenosis), and OP-1 (orthopaedic reconstruction, partnered with Stryker).

Key Financial Metrics

Note: The 2000 financial results include a one-time non-cash charge of $294.8 million for in-process research and development (IPR&D) acquired in the merger, as well as significant stock-based compensation and amortization of intangible assets.

Material Changes vs. Prior Period

• Merger Impact: The 2000 results reflect the consolidation of Creative, Ontogeny, and Reprogenesis. This resulted in a massive increase in operating expenses and a significant non-cash charge for acquired IPR&D ($294.8 million) and amortization of goodwill/intangibles ($14.5 million).
• Revenue Decline: Total revenues decreased 68% to $1.0 million, primarily due to the termination of a research agreement with Biogen in 1999, partially offset by $319,000 in NIST grant revenue.
• Expense Surge: R&D expenses increased 67% and General & Administrative expenses increased 69% due to the combined operations of the three entities and merger-related costs (severance, legal fees).
• Stock-Based Compensation: Increased from $64,000 in 1999 to $16.6 million in 2000, driven by the amortization of deferred compensation from the merger and option grants.
• Liquidity Improvement: Cash and marketable securities increased significantly to $75.8 million, bolstered by a private placement of 5.2 million shares in November 2000 yielding approximately $43.3 million in net proceeds.

Guidance, Outlook, and Risks

• Outlook: Management anticipates spending approximately $40 million in operations for each of 2001 and 2002. The company expects to incur additional operating losses for the foreseeable future and has no current products generating significant revenue.
• Regulatory Status:
  • OP-1 (Stryker): Recommended for approval in Europe and Australia for non-union fractures. However, the FDA issued a "Not Approvable" letter in January 2001 for the U.S. PMA, requiring a new clinical trial, which delays potential royalty revenue.
  • Chondrogel: Phase III trial enrollment completed in September 2000; data expected late 2001. BLA submission expected in 2002.
  • Vascugel: Phase I clinical study initiated in Q1 2001.
• Risks:
  • Capital Requirements: The company estimates it needs at least $80 million to fund operations through the end of 2002. While current cash reserves are sufficient into Q4 2002, additional financing may be required, potentially causing dilution.
  • Dependency on Partners: Future revenue is heavily dependent on Stryker's ability to commercialize OP-1 and generate royalties.
  • Regulatory Uncertainty: Novel technologies (cell therapies, tissue engineering) face uncertain regulatory pathways and potential delays.

Investor Verification Checklist

• OP-1 Regulatory Path: Verify the timeline and design of the new clinical trial required by the FDA for OP-1 approval in the U.S.
• Cash Burn Rate: Confirm the company's ability to fund the projected $40 million annual operating spend without immediate additional equity dilution.
• Chondrogel Trial Data: Monitor the release of Phase III data expected in late 2001, which is critical for the 2002 BLA filing.
• Merger Integration: Assess the successful integration of the three predecessor companies and retention of key scientific personnel.
• Government Grants: Verify the status and renewal of NIST grants, which provide a portion of current revenue.